Details

Autor(en) / Beteiligte

• Attal, Michel
• Lauwers-Cances, Valerie
• Marit, Gerald
• Caillot, Denis
• Moreau, Philippe
• Facon, Thierry
• Stoppa, Anne Marie
• Hulin, Cyrille
• Benboubker, Lofti
• Garderet, Laurent
• Decaux, Olivier
• Leyvraz, Serge
• Vekemans, Marie-Christiane
• Voillat, Laurent
• Michallet, Mauricette
• Pegourie, Brigitte
• Dumontet, Charles
• Roussel, Murielle
• Leleu, Xavier
• Mathiot, Claire
• Payen, Catherine
• Avet-Loiseau, Hervé
• Harousseau, Jean-Luc

Titel

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Ist Teil von

• The New England journal of medicine, 2012-05, Vol.366 (19), p.1782-1791

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Lenalidomide maintenance after stem-cell transplantation significantly prolonged progression-free and event-free survival in patients with multiple myeloma. At 4 years, overall survival was similar in the lenalidomide-treated and placebo-treated groups. During the past decade, high-dose chemotherapy with autologous stem-cell transplantation has become the standard treatment for newly diagnosed myeloma in patients younger than 65 years of age. However, the median duration of response after this procedure does not exceed 3 years, and few patients remain free of the disease for more than 10 years. 1 – 4 Relapses are due to the failure of high-dose chemotherapy to eradicate all myeloma cells. Maintenance treatments have been proposed to control the proliferation of residual malignant cells after transplantation. For many years, interferon with or without glucocorticoids was used, 1 , 2 , 5 but this approach was . . .